Abstract View
Respiratory Drug Development and Lovelace Biomedical: 2010-2021
JACOB MCDONALD, Philip Kuehl, Lovelace Biomedical
Abstract Number: 483
Working Group: History of Aerosol Science
Abstract
Lovelace Biomedical has a long history of aerosol science research, dating back to 1966. Dr. Roger McClellan has submitted a parallel abstract to define the legacy of aerosol research performed at the organization from 1966-2010. The intent of this presentation is to describe the transition of the focus of the organization over the past decade to the use of aerosols for respiratory drug development, alternative tobacco, cannabis and bioaerosols. This transition was performed to best meet the needs of society and the resources that are available at Lovelace to perform nonclinical and clinical studies under regulatory scrutiny. The laboratory has placed itself as a premier site for the conduct of drug development to target the nose and lung to target myriad diseases. The current emphasis builds on the legacy of work that was performed over the first 50 years, and looks forward to continue to build on a strong foundation in aerosol science and dosimetry. The presentation will review major accomplishments and the transition of the business from 2010-2021